Navigation Links
Appointment of Mr. Kevin Buchi to Benitec Board
Date:4/11/2013

SYDNEY, April 10, 2013 /PRNewswire/ -- Benitec Biopharma Ltd (ASX: BLT), a biopharmaceutical company developing innovative therapeutics based on its gene silencing technology, DNA-directed RNA interference (ddRNAi), is very pleased to report that Mr. Kevin Buchi , CPA, has accepted an invitation to join the Company's Board of Directors. 

Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. through its $6.8 billion acquisition by Teva Pharmaceutical Industries in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, Chief Financial Officer and Head of Business Development prior to being appointed CEO.

Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics, Inc., Forward Pharma A/S and Alexza Pharmaceuticals, Inc. Mr. Buchi has served on the Board of Directors of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc. and Mesoblast Limited (Australia). Mr. Buchi has served as a Member of the Life Sciences Advisory Board at Safeguard Scientifics, Inc.

Mr. Buchi originally trained as a synthetic organic chemist for the Eastman Kodak Company graduating from Cornell University with a Bachelor of Arts degree in chemistry. He holds a Master's degree in management from the Kellogg Graduate School of Management at Northwestern University and is a Certified Public Accountant. He resides in Pennsylvania in the United States.

Benitec Biopharma's Chairman, Mr. Peter Francis , welcomed Mr Buchi's appointment. "Kevin's impressive track record in the international biotechnology and pharmaceutical industry over 30 years provides Benitec with significant additional business development strength, and importantly, networking capacity in the United States and Europe. The Directors and Management look forward to working closely with Kevin to achieve the Company's aims through industry partnerships. We see this as a validation of Benitec's corporate strategy over the past few years."

Mr. Buchi commented, "I continue to be impressed with Benitec's programs and progress. The expected entry of the Company's Hepatitis C therapy into the clinic later this year is validation of that progress.  I believe that Benitec Biopharma's technology and programs have the potential to bring about a revolution in treatment of many diseases and conditions through the power of DNA-directed RNA interference. I look forward to working with the Company to help advance its exciting programs and vision."

For more information please contact:
Dr. Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.


'/>"/>
SOURCE Benitec Biopharma Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
2. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
3. Store-A-Tooth™ Stem Cell Banking Announces Appointment of Dedicated Sales Representative in New England
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
6. Mobility and Big Data Analytics Provider NuWare Announces the Appointment of Rohit Shyam as Chief Strategy & Marketing Officer
7. Store-A-Tooth™ Dental Stem Cell Banking Announces Appointment of Dedicated Representative in South Florida
8. Sequenom Announces Leadership Appointments
9. T1D Exchange Announces Appointment of Dana Ball as Chief Executive Officer
10. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
11. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... ... Parallel6™ , the leader in mClinical™ technologies for improving patient enrollment, ... of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma Tech ... take pride in honoring Parallel6 as one of the top 10 companies that are ...
(Date:4/20/2017)... , April 20, 2017 Dutch philosopher Koert van Mensvoort ... Nature, at the University of Technology in Eindhoven - has written a ... letter, he calls on humanity to avoid becoming a slave and victim to ... ... Dutch philosopher Koert van Mensvoort – founder of the Next ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... ... A number of new instruments have recently emerged to accommodate different applications ... and Cell Analysis Education Webinar Series , will focus on advances in the Invitrogen™ ... applications. , Many flow cytometers have unique capabilities and the Attune NxT Flow ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/20/2017)... HANOVER, Germany , March 20, 2017 At ... Hamburg -based biometrics manufacturer DERMALOG. The Chancellor came to the ... Japan is this year,s CeBIT partner country. At the largest ... important biometrics in use: fingerprint, face and iris recognition as well as ... ...
Breaking Biology News(10 mins):